Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial - Concepedia

Concepedia

Publication | Open Access

Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

DOI Full Paper Access

197

Citations

41

References

2019

Year

Seyed Ali Jazayeri-Tehrani, Seyed Mahdi Rezayat, Siavash Mansouri, Mostafa Qorbani, Seyed Moayed Alavian, Milad Daneshi‐Maskooni, Mohammad Javad Hosseinzadeh‐Attar

Nutrition & Metabolism

Abstract

Iranian Registry of Clinical Trials, IRCT2016071915536N3. Registered 2016-08-02.

References

	Year	Citations

Page 1